Liang H - Search Results

1

A Randomized Controlled Trial Comparing Two Different Schedules for Cisplatin Treatment in Patients with Locoregionally Advanced Nasopharyngeal Cancer.

Xia WX, Lv X, Liang H, Liu GY, Sun R, Zeng Q, Li SW, Mo HY, Han F, Luo DH, Liu Q, Shi MY, Ye YF, Yang J, Ke LR, Qiang MY, Qiu WZ, Yu YH, Liu KY, Huang XJ, Li WZ, Lv SH, Cai ZC, Miao JJ, Guo L, Chen MY, Cao KJ, Wang L, Zhao C, Huang PY, Chen QY, Hua YJ, Tang LQ, Qian CN, Mai HQ, Guo X, Xiang YQ. Xia WX, et al. Among authors: liang h. Clin Cancer Res. 2021 Aug 1;27(15):4186-4194. doi: 10.1158/1078-0432.CCR-20-4532. Epub 2021 Jun 3. Clin Cancer Res. 2021. PMID: 34083231 Free PMC article. Clinical Trial.

2

CCL2-CCR2 axis promotes metastasis of nasopharyngeal carcinoma by activating ERK1/2-MMP2/9 pathway.

Yang J, Lv X, Chen J, Xie C, Xia W, Jiang C, Zeng T, Ye Y, Ke L, Yu Y, Liang H, Guan XY, Guo X, Xiang Y. Yang J, et al. Among authors: liang h. Oncotarget. 2016 Mar 29;7(13):15632-47. doi: 10.18632/oncotarget.6695. Oncotarget. 2016. PMID: 26701209 Free PMC article.

3

A prognostic model predicts the risk of distant metastasis and death for patients with nasopharyngeal carcinoma based on pre-treatment interleukin 6 and clinical stage.

Ke L, Xiang Y, Xia W, Yang J, Yu Y, Ye Y, Liang H, Guo X, Lv X. Ke L, et al. Among authors: liang h. Clin Immunol. 2016 Mar;164:45-51. doi: 10.1016/j.clim.2016.01.004. Epub 2016 Jan 15. Clin Immunol. 2016. PMID: 26780676

4

c-Src activation promotes nasopharyngeal carcinoma metastasis by inducing the epithelial-mesenchymal transition via PI3K/Akt signaling pathway: a new and promising target for NPC.

Ke L, Xiang Y, Guo X, Lu J, Xia W, Yu Y, Peng Y, Wang L, Wang G, Ye Y, Yang J, Liang H, Kang T, Lv X. Ke L, et al. Among authors: liang h. Oncotarget. 2016 May 10;7(19):28340-55. doi: 10.18632/oncotarget.8634. Oncotarget. 2016. PMID: 27078847 Free PMC article.

5

A model to predict the risk of lethal nasopharyngeal necrosis after re-irradiation with intensity-modulated radiotherapy in nasopharyngeal carcinoma patients.

Yu YH, Xia WX, Shi JL, Ma WJ, Li Y, Ye YF, Liang H, Ke LR, Lv X, Yang J, Xiang YQ, Guo X. Yu YH, et al. Among authors: liang h. Chin J Cancer. 2016 Jun 29;35(1):59. doi: 10.1186/s40880-016-0124-0. Chin J Cancer. 2016. PMID: 27357728 Free PMC article. Clinical Trial.

6

Comparison of the short-term efficacy between docetaxel plus carboplatin and 5-fluorouracil plus carboplatin in locoregionally advanced nasopharyngeal carcinoma.

Lv X, Xia WX, Ke LR, Yang J, Qiu WZ, Yu YH, Liang H, Huang XJ, Liu GY, Zeng Q, Guo X, Xiang YQ. Lv X, et al. Among authors: liang h. Onco Targets Ther. 2016 Aug 18;9:5123-31. doi: 10.2147/OTT.S103729. eCollection 2016. Onco Targets Ther. 2016. PMID: 27574453 Free PMC article.

7

Survival impact of waiting time for radical radiotherapy in nasopharyngeal carcinoma: A large institution-based cohort study from an endemic area.

Liang H, Xiang YQ, Lv X, Xie CQ, Cao SM, Wang L, Qian CN, Yang J, Ye YF, Gan F, Ke LR, Yu YH, Liu GY, Qiu WZ, Huang XJ, Wen CH, You N, Wang XQ, Guo X, Xia WX. Liang H, et al. Eur J Cancer. 2017 Mar;73:48-60. doi: 10.1016/j.ejca.2016.12.009. Epub 2017 Feb 3. Eur J Cancer. 2017. PMID: 28161498

8

Safety and efficacy of lobaplatin combined with 5-fluorouracil as first-line induction chemotherapy followed by lobaplatin-radiotherapy in locally advanced nasopharyngeal carcinoma: preliminary results of a prospective phase II trial.

Ke LR, Xia WX, Qiu WZ, Huang XJ, Yang J, Yu YH, Liang H, Liu GY, Ye YF, Xiang YQ, Guo X, Lv X. Ke LR, et al. Among authors: liang h. BMC Cancer. 2017 Feb 15;17(1):134. doi: 10.1186/s12885-017-3080-4. BMC Cancer. 2017. PMID: 28202000 Free PMC article. Clinical Trial.

9

Combining cetuximab with chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma: A propensity score analysis.

Xia WX, Liang H, Lv X, Wang L, Qian CN, Ye YF, Ke LR, Qiu WZ, Yu YH, Huang XJ, Liu GY, Zhao C, Xiang YQ, Guo X. Xia WX, et al. Among authors: liang h. Oral Oncol. 2017 Apr;67:167-174. doi: 10.1016/j.oraloncology.2017.02.026. Epub 2017 Mar 2. Oral Oncol. 2017. PMID: 28351572

10

A phase II trial of induction NAB-paclitaxel and cisplatin followed by concurrent chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma.

Ke LR, Xia WX, Qiu WZ, Huang XJ, Yu YH, Liang H, Liu GY, Xiang YQ, Guo X, Lv X. Ke LR, et al. Among authors: liang h. Oral Oncol. 2017 Jul;70:7-13. doi: 10.1016/j.oraloncology.2017.04.018. Epub 2017 May 9. Oral Oncol. 2017. PMID: 28622892 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

12,241 results

Search Page